{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:35:41Z","timestamp":1791063341957,"version":"4.1.0"},"reference-count":54,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2004,4,20]],"date-time":"2004-04-20T00:00:00Z","timestamp":1082419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although conventional doxorubicin is associated with favorable clinical outcomes in patients with a variety of tumor types, it long has been associated with the risk of development of cardiotoxicity. Therefore, researchers have focused their efforts on the development of new formulations to improve efficacy while minimizing associated toxicities. The most successful strategy reported to date has been liposomal encapsulation, which alters the pharmacokinetics of the drug, with the goal of maintaining efficacy and improving the therapeutic index. The cardiac profiles of three liposomal anthracyclines, liposomal daunorubicin, nonpegylated liposomal doxorubicin, and pegylated liposomal doxorubicin, were reviewed. More studies will be needed to determine the cardiac safety of liposomal daunorubicin. Although nonpegylated liposomal doxorubicin demonstrated more favorable cardiac safety compared with conventional doxorubicin, its cardiac safety appeared to be mitigated when high bolus doses were administered. Of the liposomal formulations, the strongest evidence of cardiac safety was observed with pegylated liposomal doxorubicin. Compared with conventional doxorubicin, pegylated liposomal doxorubicin was associated with a significantly lower risk of development of cardiac events (<jats:italic>P<\/jats:italic> &lt; 0.001). Moreover, the risk of cardiotoxicity was not increased in patients who were treated with pegylated liposomal doxorubicin at cumulative doses &gt; 450 mg\/m<jats:sup>2<\/jats:sup> or in patients at increased risk for cardiotoxicity, such as those with prior adjuvant doxorubicin use. Liposomal doxorubicin formulations provided a favorable advantage over conventional doxorubicin in terms of cardiac safety. Recent evidence also suggests that the improved cardiac safety of liposomal doxorubicin formulations is reflected by their successful use in combination with trastuzumab and other chemotherapy agents. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.20207","type":"journal-article","created":{"date-parts":[[2004,4,20]],"date-time":"2004-04-20T16:00:29Z","timestamp":1082476829000},"page":"2052-2063","source":"Crossref","is-referenced-by-count":113,"title":["Cardiac profiles of liposomal anthracyclines"],"prefix":"10.1002","volume":"100","author":[{"given":"Maria","family":"Theodoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,4,20]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022040-00002"},{"key":"e_1_2_11_3_2","first-page":"2403","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"Balmer C","year":"1997"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124120-00004"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6355"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700544-00003"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-710"},{"key":"e_1_2_11_8_2","unstructured":"WiglerN O'BrienM RossoR et al.Reduced cardiac toxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin (CAELYX\u2122\/Doxil) vs. doxorubicin for first\u2010line treatment of metastatic breast cancer. Poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology May 18\u201321 2002 Orlando Florida."},{"key":"e_1_2_11_9_2","volume-title":"Adriamycin RDF\u00ae\/Adriamycin PFS\u00ae (doxorubicin hydrochloride for injection) [package insert]","author":"Pharmacia & Upjohn Company","year":"2002"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(93)90036-Q"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11407"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-1-199607010-00008"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_2_11_14_2","first-page":"2330","volume-title":"Cancer medicine","author":"Ewer MS","year":"2002"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-96-2-133"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/clon.2000.9141"},{"key":"e_1_2_11_17_2","first-page":"145","article-title":"Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer","volume":"3","author":"Seymour L","year":"1999","journal-title":"Cancer Prev Control."},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.117"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1333"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1318"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700544-00005"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/10611869609015970"},{"key":"e_1_2_11_23_2","volume-title":"DaunoXome\u00ae (daunorubicin citrate liposome injection) [package insert]","author":"Gilead Sciences, Inc","year":"2000"},{"key":"e_1_2_11_24_2","volume-title":"Myocet\u2122 (doxorubicin HCl liposome injection) product information","author":"Elan Pharmaceuticals","year":"2000"},{"key":"e_1_2_11_25_2","volume-title":"Doxil\u00ae (doxorubicin HCl liposome injection) [package insert]","author":"Ortho Biotech Products","year":"2001"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10201"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1444"},{"key":"e_1_2_11_28_2","first-page":"284a","article-title":"A Phase I\/II trial of liposomal doxorubicin (TLC D\u201099, Myocet) with cyclophosphamide, vincristine, and prednisone in newly diagnosed aggressive non\u2010Hodgkins lymphoma","volume":"21","author":"Levine AM","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_11_29_2","first-page":"285a","article-title":"Treatment of newly diagnosed AIDS\u2010related lymphomas with liposomal doxorubicin (TLC\u2010D99, Myocet) combined with cyclophosphamide, vincristine, and prednisone: results of a Phase I\/II trial","volume":"21","author":"Tulpule A","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_11_30_2","unstructured":"TheodoulouM CamposSM BatistG et al.TLC D\u201099 (D Myocet\u2122) and Herceptin\u2122 (H) is safe in advanced breast cancer: final cardiac safety and efficacy analysis. Poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology May 18\u201321 2002 Orlando Florida."},{"key":"e_1_2_11_31_2","first-page":"431","article-title":"Liposomal anthracyclines","volume":"8","author":"Gabizon AA","year":"1994","journal-title":"Hematol Oncol Clin North Am."},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-22115-0_11"},{"key":"e_1_2_11_33_2","first-page":"751","article-title":"Pharmacological\u2010toxicological expert report. CAELYX (stealth liposomal doxorubicin HCl)","volume":"15","author":"Working PK","year":"1996","journal-title":"Hum Exp Toxicol."},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008216430806"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008365716693"},{"key":"e_1_2_11_36_2","unstructured":"GabizonAA LyassO.Cardiac safety of pegylated liposomal doxorubicin demonstrated by endomyocardial biopsy in patients with advanced malignancies. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology May 31\u2013June 3 2003 Chicago Illinois."},{"key":"e_1_2_11_37_2","first-page":"291b","article-title":"Decreased risk of cardiotoxicity with long\u2010term use of Doxil\u00ae\/Caelyx\u2122 at high lifetime cumulative doses in patients with AIDS\u2010related Kaposi's sarcoma (KS)","volume":"20","author":"Mustafa MH","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.996"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2353"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80088-3"},{"key":"e_1_2_11_41_2","first-page":"217a","article-title":"Absence of cardiac toxicity in patients who received 600 mg\/m2 of liposomal encapsulated daunorubicin (DaunoXome\u00ae)","volume":"16","author":"Cohen P","year":"1997","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600344"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03292.x"},{"key":"e_1_2_11_44_2","first-page":"1381","article-title":"Age\u2010related Adriamycin cardiotoxicity in children","volume":"62","author":"Pratt CB","year":"1978","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90315-1"},{"key":"e_1_2_11_46_2","first-page":"109a","article-title":"Cardiac toxicity may limit the usefulness of liposomal daunorubicin (DaunoXome): results of a phase I study in children with relapsed or resistant tumours\u2014a UKCCSG\/SFOP study","volume":"21","author":"Lowis S","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_11_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(76)80018-7"},{"key":"e_1_2_11_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1435"},{"key":"e_1_2_11_49_2","first-page":"71","article-title":"Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy","volume":"3","author":"Billingham M","year":"1984","journal-title":"Cancer Treat Symp."},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.719"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"issue":"4","key":"e_1_2_11_52_2","first-page":"78","article-title":"Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2\/neu\u2010overexpressing metastatic breast cancer","volume":"26","author":"Baselga J","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_11_53_2","unstructured":"TrigoJ ClimentMA LluchA et al.Liposomal doxorubicin (Myocet\u00ae) in combination with Herceptin\u00ae and paclitaxel is active and well tolerated in patients with HER2\u2010positive locally advanced or metastatic breast cancer (LA\/MBC): a Phase II study. Poster presented at the 26th Annual San Antonio Breast Cancer Symposium December 3\u20136 2003 San Antonio Texas."},{"key":"e_1_2_11_54_2","unstructured":"WolffAC BonettiM SparanoJA WangM DavidsonNE on behalf of theEastern Cooperative Oncology Group.Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2\u2010positive metastatic breast cancer: preliminary results of ECOG 3198. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology May 31\u2013June 3 2003 Chicago Illinois."},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-suppl_2-17"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20207","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:27:41Z","timestamp":1760293661000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20207"}},"subtitle":["Greater cardiac safety versus conventional doxorubicin?"],"short-title":[],"issued":{"date-parts":[[2004,4,20]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,5,15]]}},"alternative-id":["10.1002\/cncr.20207"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20207","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,20]]}}}